Table 2.

Biodefense vaccines and therapeutics in phase 2 or phase 3 clinical trials

Bioterror agent	Company (location)	Type of product	Name	Stage
Anthrax	VaxGen	Vaccine	rPA102 anthrax vaccine	Phase 2
Plague	Defence Science and Technology Laboratories (Porton Down, UK)	Vaccine	F1/V combination recombinant subunit plague vaccine	Phase 2
Smallpox	Acambis	Vaccine	ACAM2000	Phase 3
Smallpox	Acambis	Vaccine	MVA3000	Phase 2
Smallpox	Bavarian Nordic (Kvistgard, Denmark)	Vaccine	IMVAMUNE	Phase 2
Dengue	Acambis/Sanofi Pasteur	Vaccine	ChimeriVax-Dengue	Phase 2
Dengue	GlaxoSmithKline Biologicals (Rixensart, Belgium)	Vaccine	Attenuated tetravalent dengue vaccine	Phase 2
Dengue	Sanofi Pasteur	Vaccine	Attenuated tetravalent dengue vaccine	Phase 2
Food and waterborne bacteria	AVANT Immunotherapeutics (Needham, MA, USA)	Vaccine	CholeraGarde	Phase 2
Food and waterborne bacteria	Emergent Europe (Wokingham, UK)	Vaccine	Oral typhoid vaccine	Phase 2
Food and waterborne bacteria	Teijin Pharma (Tokyo)	Therapeutic	Humanized mAb	Phase 2
Food and waterborne bacteria	AVANT Immunotherapeutics	Vaccine	Ty800 typhoid vaccine	Phase 1/2
Food and waterborne bacteria	Iomai Corporation (Gaithersburg, MD, USA)	Vaccine	ETEC vaccine patch	Phase 1/2
Food and waterborne protozoa	GlaxoSmithKline	Therapeutic	Albendazole	Phase 3
Viral encephalitides	Acambis	Vaccine	ChimeriVax-JE	Phase 3
Viral encephalitides	Intercell (Vienna)	Vaccine	Japanese encephalitis vaccine	Phase 3
Viral encephalitides	Acambis	Vaccine	ChimeriVax-West Nile	Phase 2
Viral encephalitides	Hemispherx Biopharma (Philadelphia)	Therapeutic	Interferon-alpha-n3	Phase 2
Viral encephalitides	AVI BioPharma	Therapeutic	AVI-4020	Phase 1b/2
Viral encephalitides	OMRIX Biopharmaceuticals (New York)	Therapeutic	Omr-IgG-am	Phase 1/2

Source: ref. 1.